GFAP and epilepsy: Serum glial fibrillary acidic protein (GFAP), detectable with ultrasensitive assays such as Simoa, serves as a marker of astrocytic injury that correlates with disease severity and seizure burden, though it lacks specificity to epilepsy as it elevates in various neurodegenerative conditions [29].